Cytori Therapeutics Company Profile (NASDAQ:CYTX)

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CYTX
  • CUSIP: 23283K10
  • Web:
  • Market Cap: $15.42 million
  • Outstanding Shares: 32,478,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $1.32
  • 52 Week Range: $0.41 - $2.29
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.06
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $10.07 million
  • Price / Sales: 1.53
  • Book Value: $0.31 per share
  • Price / Book: 1.53
  • EBIDTA: ($18,720,000.00)
  • Net Margins: -491.71%
  • Return on Equity: -177.92%
  • Return on Assets: -62.73%
  • Debt-to-Equity Ratio: 1.28%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.62%
  • Average Volume: 672,827 shs.
  • Beta: 3.04
  • Short Ratio: 2.34
Frequently Asked Questions for Cytori Therapeutics (NASDAQ:CYTX)

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Shares of Cytori Therapeutics reverse split on Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.26) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.05. The company earned $0.60 million during the quarter, compared to analyst estimates of $2.32 million. Cytori Therapeutics had a negative net margin of 491.71% and a negative return on equity of 177.92%. The firm's quarterly revenue was down 53.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) earnings per share. View Cytori Therapeutics' Earnings History.

Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?

2 brokers have issued twelve-month target prices for Cytori Therapeutics' shares. Their forecasts range from $2.30 to $10.00. On average, they expect Cytori Therapeutics' share price to reach $6.15 in the next twelve months. View Analyst Ratings for Cytori Therapeutics.

What are analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (7/12/2017)
  • 2. Maxim Group analysts commented, "With the closure of the Azaya acquisition announced this morning, we now assume a 15% market share and 35% royalty rate for the $300M European Liposomal Doxorubicin market with the first year of commercial sales in 2019. We recognize that a US fast track strategy could put Cytori's Doxorubicin in the US market (even before Europe) but for conservatism we do not assume US revenues in our model (nor do we assume Japan, or any other geographies which will likely evolve as well). We believe our 15% share and 35% royalty rates are both realistic (and market share could be conservative). The result of these changes is our valuation target now changes from $6 to $10 per share." (2/15/2017)

Who are some of Cytori Therapeutics' key competitors?

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:

  • David M. Rickey, Independent Chairman of the Board
  • Marc H. Hedrick M.D., President, Chief Executive Officer, Director
  • Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Seijiro N. Shirahama, President , Asia Pacific
  • John David Harris, Vice President, General Manager - Cell Therapy
  • Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
  • Mark Marino M.D., Chief Medical Officer
  • Gregg A. Lapointe, Director
  • Richard James Hawkins, Independent Director
  • Gary A. Lyons, Independent Director

How do I buy Cytori Therapeutics stock?

Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytori Therapeutics' stock price today?

One share of Cytori Therapeutics stock can currently be purchased for approximately $0.47.

MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $6.15 (1,195.01% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2017B. RileyDowngradeBuy -> NeutralLowView Rating Details
7/10/2017Maxim GroupSet Price TargetBuy$10.00HighView Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
Earnings by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Earnings History by Quarter for Cytori Therapeutics (NASDAQ CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.31)($0.26)$2.32 million$0.60 millionViewN/AView Earnings Details
3/23/2017Q4 16($0.23)($0.24)$3.36 million$1.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.24)($0.26)$2.85 million$2.61 millionViewListenView Earnings Details
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$2.90 million$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.03)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.09)($0.12)$4.31 million$1.10 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.11)($0.15)$2.76 million$0.94 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
2017 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cytori Therapeutics (NASDAQ:CYTX)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 8.65%
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Institutional Ownership by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.00View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cytori Therapeutics (NASDAQ:CYTX)
Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
DateHeadline logoCytori Therapeutics (CYTX) STAR Trial of Habeo Cell Therapy in Patients with Scleroderma Doesn't Met Primary Endpoint - July 24 at 10:28 PM logoAnalysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR) - July 24 at 5:26 PM logoCytori Says STAR Trial Fails To Meet Primary Or Secondary Efficacy Endpoints - July 24 at 10:47 AM logoCytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma - July 24 at 10:47 AM logoZacks Investment Research Lowers Cytori Therapeutics Inc (CYTX) to Hold - July 12 at 7:10 PM logoCytori Therapeutics Inc (NASDAQ:CYTX) Upgraded to "Buy" at Zacks Investment Research - July 11 at 9:04 PM logoCytori Therapeutics (CYTX) Says AMA Approves New Category III ... - - July 10 at 5:39 PM logoAmerican Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy - July 10 at 5:39 PM logoAre Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? - Nasdaq - July 8 at 10:07 AM logoCytori Therapeutics (CYTX) Issued Key Patents for Scleroderma - - July 8 at 10:07 AM logoAre Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? - July 8 at 10:07 AM logoPre-Open Movers 07/06: (HSNI) (BGNE) (CYTX) Higher; (EGLT) (TAHO) (AZZ) Lower (more...) - July 6 at 3:16 PM logoETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017 - July 5 at 6:27 PM logoCytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America - June 14 at 5:36 PM logoCytori Therapeutics (CYTX) Publishes Long-Term Safety Data on ... - - June 8 at 10:41 PM logoCytori Publishes Long Term Safety Data On Technology For Breast Reconstruction - June 8 at 10:06 AM logoLong Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy - June 8 at 10:06 AM logoETFs with exposure to Cytori Therapeutics, Inc. : June 6, 2017 - June 6 at 4:56 PM logoValuEngine Lowers Cytori Therapeutics Inc (CYTX) to Strong Sell - June 4 at 9:16 PM logoCytori Therapeutics Inc (CYTX) PT Set at $10.00 by Maxim Group - June 1 at 11:02 PM logoCytori to Introduce Next-Generation Celution® Technology - GlobeNewswire (press release) - June 1 at 10:17 PM logoCytori to Introduce Next-Generation Celution® Technology - June 1 at 5:16 PM logoCytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial - May 31 at 9:58 AM logoCytori Therapeutics Inc (CYTX) Short Interest Update - May 28 at 7:16 AM logoETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017 - May 25 at 6:25 PM logoCytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 - May 24 at 12:38 PM logoCytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial - May 23 at 12:32 PM logoCytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference - May 16 at 12:06 PM logoFY2019 EPS Estimates for Cytori Therapeutics Inc Lowered by B. Riley (CYTX) - May 15 at 10:10 AM logoB. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc (CYTX) - May 14 at 10:14 PM logoCytori Therapeutics Inc (CYTX) Sees Significant Drop in Short Interest - May 13 at 7:44 AM logoCytori Therapeutics Inc (CYTX) Raised to "Hold" at Zacks Investment Research - May 12 at 7:41 PM logoEdited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT - May 12 at 5:10 PM logoCytori Therapeutics Inc (CYTX) Issues Earnings Results - May 12 at 3:12 PM logoQ1 2017 Earnings Estimate for Cytori Therapeutics Inc (CYTX) Issued By B. Riley - May 12 at 7:48 AM logoEARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q1 Earnings Report - May 11 at 10:18 PM logoCytori reports 1Q loss - May 11 at 10:18 PM logoCytori Reports First Quarter 2017 Business and Financial Results - May 11 at 5:17 PM logoOne Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial - May 10 at 4:49 PM logoCytori Therapeutics Announces Inducement Grants for New Employees - May 5 at 9:53 PM logoCytori Therapeutics (CYTX) Receives News Sentiment Rating of 0.35 - May 3 at 1:24 PM logoCytori to Webcast First Quarter Financial Results on May 11 - April 27 at 5:10 PM logoSomewhat Negative Press Coverage Somewhat Unlikely to Affect Cytori Therapeutics (CYTX) Share Price - April 24 at 2:01 PM logoCritical Media Coverage Very Unlikely to Impact Cytori Therapeutics (CYTX) Share Price - April 21 at 7:47 AM logoCytori Therapeutics (CYTX) Earns Media Impact Score of 0.29 - April 18 at 1:54 PM logoCytori Therapeutics (CYTX) Getting Somewhat Favorable News Coverage, Report Finds - April 15 at 1:21 PM logoCytori Therapeutics (CYTX) IDE Approved by FDA for Pilot Clinical Trial to Evaluate Cytori Cell Therapy - April 11 at 12:56 PM logoCytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount - April 11 at 12:56 PM logoCytori Therapeutics Stock Sliding on Offering Price Discount - April 11 at 12:56 PM logoCytori Therapeutics -36% after pricing 8.6M-share offering at $1.10 - April 11 at 9:51 AM



Cytori Therapeutics (CYTX) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff